- The company said that laromestorcel infusions resulted in clinically meaningful, dose-and time-dependent increases in the primary endpoint of the 6-minute walk test compared with placebo.
- The company was evaluating whether its investigational therapy improves physical functioning in 148 ambulatory individuals with frailty.
- The therapy is currently being evaluated in multiple indications including hypoplastic left heart syndrome (HLHS) and Alzheimer’s disease (AD).
Shares of Longeveron Inc. (LGVN) rose 7% on Wednesday, before paring back gains, after the company announced positive results from the trial of its investigational therapy in age-related clinical frailty.
The company said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo, in a study.
LGVN shares traded 9% lower at the time of writing.
Trial Outcomes
The company said that laromestorcel infusions resulted in clinically meaningful, dose-and time-dependent increases in the primary endpoint of the 6-minute walk test compared with placebo. The 6-Minute Walk Test (6MWT) is a submaximal, standardized exercise test measuring the distance a patient can walk on a flat, hard surface in six minutes.
“We are highly encouraged by these Phase 2b results that demonstrate the potential of stem cell therapy to improve the condition of patients with aging-related frailty,” said Joshua M. Hare, Chief Science Officer at Longeveron. “Those with Aging Frailty are disproportionately compromised in their ability to cope with every day and acute stressors, are at high vulnerability to disease and injury, and are at increased risk for poor outcomes and death after surgery.”
Laromestrocel, the company’s lead investigational product, is a human bone marrow-derived allogeneic stem cell (MSC) investigational therapy. The company was evaluating whether it improves physical functioning in 148 ambulatory individuals with frailty. The therapy is currently being evaluated in multiple indications including hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Pediatric Dilated Cardiomyopathy (DCM).
How Did Stocktwits Users React?
On Stocktwits, retail sentiment around LGVN stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.
A Stocktwits user said that positive news from the company never helps the stock price.
LGVN stock is down by 64% over the past 12 months.
Read More: Why Did ODD Shares Tumble More Than 50% Today?
For updates and corrections, email newsroom[at]stocktwits[dot]com.